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Abstract 
 
Introduction 
Xerostomia is one of side-effects of radiotherapy for head and neck cancers. No definitive method has been 
proposed for the treatment of this condition. However, pilocarpine is considered effective for the 
management of chronic xerostomia. The purpose of the present study was to assess the preventive effect of 
pilocarpine. 
Materials and Methods 
This study was performed on 34 patients with head and neck cancers, undergoing radiation therapy (5000 
cGy). The patients were randomly divided into two groups. The case group was administered 16 drops of 
pilocarpine (2%) eye drops per day, while the control group received normal saline; the treatment plan 
continued for four weeks. Unstimulated whole saliva flow rate was measured at four stages: two weeks 
before radiotherapy (baseline), the first day of radiotherapy, and two and four weeks after the initiation of 
radiotherapy. 
Results 
At baseline and the first day of radiotherapy, no significant differences were observed in the amount of saliva 
between the case and control groups (P<0.76 and P<0.054, respectively). However, by starting radiotherapy, 
a statistically significant improvement was reported in saliva production in the case group, compared to the 
control group (P<0.00); this trend continued during the next four weeks of radiotherapy (P<0.003). 
Generally, a significant difference was observed between the two groups at all stages of data evaluation 
(P<0.00). 
Conclusion 
According to the findings, pilocarpine was found to be effective for the prevention of xerostomia. Moreover, 
it could restrain the decline in the amount of saliva and reduce the rate of xerostomia. 
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1. Introduction 
Radiotherapy is one of the most frequently 
used treatments for head and neck cancers [1]. 
This treatment modality plays a significant 
role in the management of some cancers and 
can increase the chance of survival in patients; 
moreover, it can be a definite treatment in 
some cases.  
Despite its obvious advantages, head and neck 
radiotherapy is accompanied by inevitable 
side-effects such as xerostomia and decreased 
salivary flow, which can persist for a lifetime 
in some cases [1-3]. In most cases, it is 
impossible to avoid radiation-induced 
damages, which are caused by the destruction 
of serous acinar cells in the salivary glands.  
Radiation leads to a vigorous decline in the 
amount of saliva in patients undergoing 
radiotherapy [4]. Xerostomia may cause 
significant disorders such as severe pain, 
speech disorders, dysphasia, increased rate of 
dental damages, mucosal infections, atrophic 
change of tongue papillae, lobulated tongue, 
halitosis, cervical caries, disorders in nutrition 
and taste, and susceptibility to oral diseases [5, 
6]. 
Xerostomia has significant adverse effects on 
the quality of life in patients undergoing 
radiotherapy [7-10]. Moreover, it can limit the 
patients’ social activities and promote 
depression among them [11]. This condition 
can also lead to or exacerbate mucositis, which 
might limit the application of radiation therapy 
in patients [12]. 
Several methods have been proposed for the 
prevention of radiation-induced xerostomia. 
Frequent intake of liquids and use of sugar-
free gums and candies might stimulate the 
remaining salivary cells. Moreover, systemic 
sialogogues, which have all the natural 
ingredients and protective functions of saliva, 
can help stimulate saliva. In addition, 
bethanechol and cevimeline have been 
reported to be effective for the treatment of 
xerostomia [13]. 
Among sialogogues, pilocarpine has been 
introduced as the best available 
option.Pilocarpine is a parasympathomimetic 
agent, which mainly affects muscarinic 
cholinergic receptors in the acinar cells of 
salivary glands. This agent can increase the 
amount of saliva if used three times a day at a 
dosage of 5-10 mg; it should be mentioned that 
cardiovascular side-effects are limited at this 
dose range [2].  
Use of pilocarpine has been approved for the 
treatment of chronic xerostomia [14-16]. If 
used during radiotherapy, pilocarpine can be 
effective and reduce the rate of xerostomia to 
some extent[17-20] . Therefore, this agent can 
reduce the occurrence of many oral disorders, 
resulting from radiotherapy, and increase the 
patient’s quality of life. Pilocarpine, as a 
prophylactic agent, can be useful for the 
management of xerostomia and may reduce 
the rate of radiation-induced xerostomia. 
Therefore, in this clinical trial, we aimed to 
evaluate the preventive effect of pilocarpine on 
xerostomia.  
 
2. Materials and Methods 
In this double-blinded, randomized, clinical 
trial, the study population consisted of 34 
patients with head and neck cancers (i.e., 
locally advanced laryngeal cancer, locally 
advanced hypopharyngeal cancer, and 
nasopharyngeal cancer). The subjects 
underwent radiotherapy (5000 cGy), using an 
accelerator device(Neptun 10PC,IPJ-
ZdAJ,Swierk,Poland) and a protective oral 
radiation shield at Ramezanzadeh 
Radiotherapy Center, Yazd, Iran.  
The table of random numbers was used for 
randomization. The case and control groups 
each consisted of 17 patients. The control 
group received training on massage therapy of 
salivary glands and adequate hydration. They 
were administered lemon tablets, containing 
normal saline, four times a day as placebo. 
In addition to the previously mentioned 
training, the case group received four 
pilocarpine 2% eye drops, containing 2 g of 
pilocarpine in 100 ml pilocarpine 
hydrochloride (Mina Daroo Company, Iran) 
four times a day. The intervention continued 
for two weeks after radiotherapy.  
The inclusion criteria were as follows: 1) head 
and neck cancers; 2) locally advanced 
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laryngeal cancer, hypopharyngeal cancer, and 
nasopharyngeal cancer; 3) undergoing 
conventional radiotherapy with doses more 
than 50 Gy; and 4) no prior history of 
cardiovascular diseases, glaucoma, asthma, or 
gastrointestinal diseases.  
The exclusion criteria were as follows: 1) 
changes in the patient's treatment protocol or 
the process of receiving therapeutic radiation 
therapy; 2) lack of patient cooperation in the 
study process; and 3) unwillingness to 
cooperate in the sampling process at the 
specified time. 4) prior history of 
cardiovascular diseases, gastrointestinal 
disorders, or asthma. 
Unstimulated whole saliva flow rate was 
measured at four stages: two weeks before the 
first session of radiotherapy (baseline), the 
first day of radiation therapy, and two and four 
weeks after the initiation of radiotherapy. For 
this purpose, the spitting method was applied 
in which patients avoided to drink or eat 
anything 90 minutes before sampling. Then, 
after 5 minutes, the subjects were asked to spit 
their saliva into a graded test tube once or 
twice within a minute [21].  
The amount of saliva (millilitres in 5 minutes) 
was calculated and recorded by a trained 
nurse. During the study, the patients and the 
nurse, who collected the samples, were not 
aware of the type of medications; therefore, we 
could ensure the double-blinded design of the 
study. At the beginning, the number of patients 
was 40, although it reduced to 34 cases by the 
end of the study. In fact, one subject died 
during the treatment process, three cases left 
the treatment due to lack of motivation, and 
two samples did not continue radiotherapy.  
The gathered data were analyzed by SPSS 
version 18. Independent and paired t-tests, 
Chi-square, and repeated measures analysis Of 
variance were applied for data analysis. P-
value less than 0.05 was considered 
statistically significant. 
 
3. Results  
The purpose of this study was to evaluate the 
preventive effect of pilocarpine on radiation-
induced xerostomia in patients with head and 
neck cancers. The results showed that the 
amount of saliva was not significantly 
different between the case and control groups 
two weeks before radiotherapy (P<0.761).  
By starting radiotherapy, the case group 
experienced a lower rate of decline in the 
amount of saliva, compared to the control 
group (P<0.00). This protocol continued 
during the next four weeks of radiotherapy 
(P<0.003). The results are presented in Table 
1, which indicates the analysis of unstimulated 
whole saliva flow rates (ml/min) in both 
groups at two weeks before the start and four 
weeks after the onset of radiotherapy. 
Furthermore, according to repeated measures 
analysis, at different intervals during the study, 
the difference in the saliva amount was 
significant, regardless of the grouping 
(P<0.00). Generally, significant differences 
were observed in the amount of saliva between 
the two groups at all stages of evaluation 
(P<0.00). These findings showed that 
pilocarpine was effective in restraining the 
decline in the amount of saliva during 
radiotherapy and decreased the rate of 
xerostomia in patients undergoing head and 
neck radiotherapy. 
Table 1. Analysis of unstimulated whole saliva flow rates (ml/min) in the case and control groups  
 
P-value Case Group Control  Group Sampling Periods 
 Standard 
Deviation 
Average Standard 
Deviation 
Average 
0.761 0.42139 1.3588 0.57279 1.3059 Two weeks before radiotherapy 
0.054 0.51841 1.7000 0.56099 1.3294 The first day of radiotherapy 
0.001 0.52943 1.5176 0.38976 0.8765 Two weeks after the initiation of  
radiotherapy 
0.003 0.35449 0.9235 0.29803 0.5588 Four weeks after the initiation of    
radiotherapy 
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4. Discussion 
This double-blinded, randomized, placebo-
controlled study was conducted to assess the 
effectiveness of oral pilocarpine in preventing 
xerostomia among patients receiving 
radiotherapy for head and neck cancers. The 
results showed that the prophylactic oral use of 
pilocarpine could reduce the rate of radiation-
induced xerostomia and dry mouth in these 
patients. Patients undergoing pilocarpine 
therapy experienced less reduction in the 
unstimulated salivary flow during 
radiotherapy, compared to the control group. 
The obtained results were not far from 
expectation, as pilocarpine is a 
parasympathomimetic agent. The prophylactic 
use of this agent reduces the extent of damage 
to the salivary gland tissues. It also increases 
the salivary flow rate by affecting muscarinic 
cholinergic receptors of acinar cells in the 
salivary glands and stimulating the remaining 
salivary tissues [22, 23]. Cell damage is due to 
the leakage of intracellular granules containing 
proteolytic enzymes. In fact, sialogogues can 
prevent damage by reducing the number of 
intracellular granules [24]. 
Stimulation of salivary gland secretion by 
pilocarpine was studied in 1964 for the first 
time [25]. Over the past decade, the effect of 
pilocarpine at 2.5-10 mg doses has been 
evaluated in two different studies, with the 
results showing an obvious improvement in 
xerostomia in 30-40% of patients. The best 
outcomes were obtained by the use of 5 mg 
pills three times a day. Despite the decreased 
rate of xerostomia in patients, absence of 
significant changes in the salivary flow was 
notable in these studies [14, 15]. Moreover, in 
previous studies, the positive effect of 
pilocarpine in improving xerostomia was 
noted among patients undergoing radiotherapy 
[3, 16].  
Contrarily, some previous studies have noted 
the inefficiency of pilocarpine, which is 
probably due to the assessment of stimulated 
salivary flow rate[26-28]. This discrepancy 
may be also related to the evaluation of quality 
of life as a determining factor in the mentioned 
studies. In fact, quality of life may affect the 
results, since various factors such as patients’ 
cultural background, mental status, and 
attitude are involved. For instance, a previous 
study reported no difference in xerostomia 
among patients who received pilocarpine, 
despite an increase in the stimulated saliva. In 
the mentioned study, a questionnaire was used 
for assessing the patients’ quality of life [29]. 
In the majority of previous surveys, 
pilocarpine has been used as a 5 mg pill three 
times a day [3, 20, 19, 27, 28, 30, 31, 37]. 
Considering the unavailability of pilocarpine 
pills in our country, we had to use pilocarpine 
2% eye drops (four times a day, four drops 
each time) in our study. At this dosage, 
pilocarpine seems to be adequately effective, 
without causing any side-effects. Although 
some patients complained of palpitations or 
excessive sweating, their conditions were not 
severe enough to lead to withdrawal from the 
study. 
Different time periods for pilocarpine 
prescription such as two weeks [12], six and 
twelve weeks [30], six months [31], and six 
weeks, six months, and twelve months [4] 
have been considered for evaluating the 
effectiveness of pilocarpine. In our study, the 
subjects were studied for a six-week period, 
since it takes at least four weeks to assess the 
therapeutic effects of pilocarpine [32]. 
Unstimulated salivary flow rate was measured 
two weeks before radiotherapy until four 
weeks after the initiation of radiotherapy. In 
fact, multiple points of time were considered 
for assaying the patients in our study, which is 
one of its strengths. 
The amount of saliva on the first day of 
treatment with pilocarpine was recorded as the 
baseline. During the second week of the study 
by starting radiotherapy, despite an increase in 
the amount of saliva in the case group, no 
significant difference was observed between 
the two groups. Considering the proximity of 
the obtained P-value to the significance 
threshold (P=0.054), the difference might have 
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been statistically significant by increasing the 
number of study samples. 
In our study, two and four weeks after the 
initiation of radiotherapy, patients who took 
pilocarpine experienced a decline in the 
amount of saliva during radiotherapy. 
However, the amount of saliva was higher in 
these subjects, compared to the control group, 
which showed the efficiency of pilocarpine. 
In a previous study, injection of pilocarpine 
caused an increase in the amount of saliva and 
protected the salivary glands against radiation 
in animals [33]. Furthermore, in another study, 
pilocarpine prescription during radiotherapy 
could increase the salivary flow rate in the 
case group, compared to the control group 
[32]. 
In our study, pilocarpine was used before and 
during radiotherapy to evaluate its 
prophylactic and therapeutic effects. Based on 
previous research, efficiency of pilocarpine 
ends as the patient ceases to use this 
medication [32]. However, we observed 
significant differences in the salivary flow rate 
between pilocarpine and control groups four 
weeks after the onset of radiotherapy (two 
weeks after the cessation of pilocarpine 
treatment); this can be a result of long-term 
observation in our study.  
Other methods such as acupuncture and 
hyperbaric oxygen therapy have been also 
proposed for reducing xerostomia and 
increasing the salivary flow rate [34, 35, 38, 
39]. However, considering the scarcity of 
controlled studies, it is not currently possible 
to assess the efficiency of these methods. 
Amifostine has been also evaluated as a 
preventive method and has been shown to be 
effective in protecting the salivary glands. 
However, severe toxicity was reported in 7% 
of patients; also, its intravenous injection 
before radiotherapy was challenging. 
Therefore, use of pilocarpine seems to be the 
best available option due to its effectiveness 
and fewer side-effects[36]. 
In the present research, the sample size was 
more limited than some previous studies which 
was due to the low number of patients 
referring to the studied center. We decided not 
to include several centers in order to reduce 
the influence of confounding factors [4, 19, 20, 
27, 30]. 
 
5. Conclusion 
In our study, preventive use of pilocarpine 
reduced radiation-induced xerostomia in 
patients suffering from head and neck cancers; 
moreover, it led to no serious side-effects in 
patients. Therefore, prescription of pilocarpine 
might minimize the serious adverse side-
effects of radiotherapy in patients and increase 
their quality of life. 
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